NCT03583307View on ClinicalTrials.gov

Efficacy and Safety of Sirolimus to Vascular Anomalies

NACompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

February 19, 2021

Study Completion Date

February 19, 2021

Conditions

Vascular Anomaly

Interventions

DRUG

Sirolimus

Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.

Trial Locations (1)

61004·

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER

NCT03583307 - Efficacy and Safety of Sirolimus to Vascular Anomalies | Biotech Hunter | Biotech Hunter